Diastolic heart failure: What we still don't know: Looking for new concepts, diagnostic approaches, and the role of comorbidities

Herz

Volumn 37, Issue 8, 2012, Pages 875-879

  Tschope C ^a,b   Lam, C S P ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Diastolic heart failure; Heart failure with preserved ejection fraction (HFPEF); Heart failure with reduced ejection fraction (HFREF); Pathophysiology; Therapeutic approaches

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CALCIUM; CONNECTIN; IRBESARTAN; IRON;

ANEMIA; ARTICLE; CALCIUM CELL LEVEL; CHRONIC KIDNEY DISEASE; CHRONIC LUNG DISEASE; COMORBIDITY; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DIASTOLIC DYSFUNCTION; DIASTOLIC HEART FAILURE; DOPPLER ECHOCARDIOGRAPHY; DRUG TARGETING; ECHOCARDIOGRAPHY; EXTRACELLULAR MATRIX; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HUMAN; HYPOTHYROIDISM; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MORBIDITY; MORTALITY; OBESITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT SELECTION; PEPTIC ULCER; PROGNOSIS; SYSTOLIC DYSFUNCTION; BIOLOGICAL MODEL; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME;

HEART FAILURE; HUMANS; MODELS, CARDIOVASCULAR; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84878894685     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-012-3719-5     Document Type: Article

References (50)

1. Paulus WJ, Tschoepe C, Sanderson JE, Rusconi C et al (2007) How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28:2539-2550
2. Almeida P, Rodrigues J, Lourenco P, Maciel MJ et al (2012) Prognostic significance of applying the European Society of cardiology consensus algorithm for heart failure with preserved systolic function diagnosis. Clin Cardiol (Epub ahead of print
3. Tschoepe C, Westermann D (2009) Heart failure with normal ejection fraction. Pathophysiology, diagnosis, and treatment. Herz 34:89-96
4. Lam CS, Lyass A, Kraigher-Krainer E, Massaro JM et al (2007) Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 115:1982-1990
5. Zile R, Baicu CF, Gaasch WH (2004) Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350:1953-1959
6. Borlaug BA, Paulus WJ (2011) Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 32:670-679
7. Yusuf S, Pfeffer MA, Swedberg K, Granger CB et al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362:777-781
8. Massie BM, Carson PE, McMurray JJ, Komajda M et al (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359:2456-2467
9. Yamaguchi H, Yoshida J, Yamamoto K, Sakata Y et al (2004) Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 43:55-60
10. Edelmann F, Tomaschitz A, Wachter R, Gelbrich G et al (2012) Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. Eur Heart J 33:203-212
11. Borbely A, Heerebeek L van, Paulus WJ (2009) Transcriptional and posttranslational modifications of titin:implications for diastole. Circ Res 104:12-14
12. Westermann D, Savvatis K, Lindner D, Zietsch C et al (2011) Reduced degradation of the chemokine MCP-3 by matrix metalloproteinase-2 exacerbates myocardial inflammation in experimental viral cardiomyopathy. Circulation 124:2082-2093
13. Heerebeek L van, Franssen CP, Hamdani N, Verheugt FW et al (2008) Molecular and cellular basis for diastolic dysfunction. Curr Heart Fail Rep 4:13-21
14. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ et al (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26:215-225
15. Ghio S, Magrini G, Serio A, Klersy C et al (2006) Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J 27:562-568
16. Solomon SD, Verma A, Desai A, Hassanein A et al (2010) Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension 55:241-248
17. Lovelock JD, Monasky M, Jeong EM, Lardin HA et al (2012) Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res 110:841-850
18. Sabbah H, Gupta R, Imai M, Irwin E et al (2011) Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodeling in dogs with advanced heart failure. Circ Heart Fail 4:65-70
19. Schwartzenberg S, Redfield M, From AM, Sorajja P et al (2012) Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol 59:442-451
20. Kasner M, Westermann D, Schultheiss HP, Tschoepe C (2012) Diastolic heart failure and LV dyssynchrony. Curr Pharm Biotechnol (Epub ahead of print
21. Kasner M, Westermann D, Steendijk P, Gaub R et al (2007) Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study. Circulation 116:637-647
22. Kasner M, Westermann D, Lopez B, Gaub R et al (2011) Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J Am Coll Cardiol 57:977-985
23. Ohara T, Niebel CL, Stewart KC, Charonko JJ et al (2012) Loss of adrenergic augmentation of diastolic Intra-LV pressure difference in patients with diastolic dysfunction: evaluation by color M-Mode echocardiography. JACC Cardiovasc Imaging 5:861-870
24. Tschoepe C, Kasner M, Westermann D, Gaub R et al (2005) The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 26:2277-2284
25. Kasner M, Gaub R, Westermann D et al (2011) Simultaneous estimation of NT-proBNP on top to mitral flow Doppler echocardiography as an accurate strategy to diagnose diastolic dysfunction in HFNEF. Int J Cardiol 149:23-29
26. Anand IS, Rector TS, Cleland JG, Kuskowski M et al (2011) Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail 4:569-577
27. Collier P, Watson CJ, Voon V, Phelan D et al (2011) Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail 13:1087-1095
28. Krum H, Elsik M, Schneider HG, Ptaszynska A et al (2011) Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail 4:561-568
29. Santhanakrishnan R, Chong JP, Ng TP, Ling LH et al (2012) Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail (Epub ahead of print
30. De Keulenaer GW, Brutsaert DL (2011) Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum. Circulation 123:1996-2004, discussion 2005
31. Cleland JG, Tendera M, Adamus J, Freemantle N et al (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27:2338-2345
32. Solomon SD, Zile M, Pieske B, Voors A et al (2012) The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet (Epub ahead of print
33. Persson H, Lonn E, Edner M, Baruch L et al (2007) Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. J Am Coll Cardiol 49:687-694
34. Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ et al (2011) Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 124:2491-2501
35. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS et al (2011) Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 13:18-28
36. Ather S, Chan W, Bozkurt B, Aguilar D et al (2012) Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 59:998-1005
37. Kitzman DW (2012) Outcomes in patients with heart failure with preserved ejection fraction: it is more than the heart. J Am Coll Cardiol 59:1006-1007
38. McMurray JJ, Anand IS, Diaz R, Maggioni AP et al (2009) Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 11:795-801
39. Rutten FH, Cramer MJ, Lammers JW, Grobbee DE et al (2006) Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail 8:706-711
40. Barr RG, Bluemke DA, Ahmed FS, Carr JJ et al (2010) Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 362:217-227
41. Kasner M, Westermann D, Steendijk P, Drose S et al (2012) Left ventricular dysfunction induced by nonsevere idiopathic pulmonary arterial hypertension: a pressure-volume relationship study. Am J Respir Crit Care Med 186:181-189
42. Lam CS, Lyass A, Kraigher-Krainer E, Massaro JM et al (2011) Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation 124:24-30
43. Agarwal SK, Heiss G, Barr RG, Chang PP et al (2012) Airflow obstruction, lung function, and risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study. Eur J Heart Fail 14:414-422
44. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW et al (2009) Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 11:130-139
45. Lam S, Carson PE, Anand IS, Rector TS et al (2012) Sex Differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial. Circ Heart Fail 5:571-578
46. De Simone G, Devereux RB, Chinali M, Roman MJ et al (2011) Sex differences in obesity-related changes in left ventricular morphology: the Strong Heart Study. J Hypertens 29:1431-1438
47. Edelmann F, Gelbrich G, Düngen HD, Fröhling S et al (2011) Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 58:1780-1791
48. Guazzi M, Vicenzi M, Arena R, Guazzi et al (2011) PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 4:8-17
49. Jacobshagen C, Belardinelli L, Hasenfuss G, Maier LS et al (2011) Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study. Clin Cardiol 34:426-432
50. Maisch B, Alter P, Pankuweit S (2011) Diabetic cardiomyopathy-Fact or fiction? Herz 36:102-115